Penserra Capital Management’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Penserra Capital Management’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-970	Closed	-$5K	–	1637
2021 Q3	$5K	Hold	970	–	–	﹤0.01%	1418
2021 Q2	$7K	Buy	970 +30	+3%	+$213	﹤0.01%	1306
2021 Q1	$7K	Buy	940 +90	+11%	+$980	﹤0.01%	1070
2020 Q4	$7K	Buy	+850	New	+$6.97K	﹤0.01%	964

Other funds holding KLDO

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Penserra Capital Management's KLDO Position: Q4 2021 in Review

Penserra Capital Management sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q4 2021, closing a stake of 970 shares — an estimated $5K sold.

Penserra Capital Management first reported a position in KLDO in Q4 2020 and held it in 4 quarters. The position peaked at $7K in Q2 2021. 66 funds tracked by Wall St. Rank hold KLDO as of Q4 2021.

Penserra Capital Management reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Penserra Capital Management sold 970 Kaleido Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $5K.
Penserra Capital Management first reported a position in Kaleido Biosciences, Inc. Common Stock in Q4 2020 and held it in 4 quarters.
Penserra Capital Management's Kaleido Biosciences, Inc. Common Stock position peaked at $7K in Q2 2021.
66 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.